[18F]1b

[18F]1b is a fluorine-18 labeled radiopharmaceutical developed as a positron emission tomography (PET) imaging agent for the detection of prostate cancer. It is a Lys-Urea-Glu-based oxime derivative of the FDA-approved PSMA-targeted agent [18F]DCFPyL. The tracer was designed to target the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells. [18F]1b was developed as part of a series of oxime-functionalized PSMA inhibitors aimed at optimizing pharmacokinetic properties, such as improving kidney clearance and tumor-to-background ratios. Preclinical studies in human prostate cancer cell lines (PC3+) and tumor xenografts have demonstrated that [18F]1b maintains high binding affinity for PSMA and exhibits specific tumor uptake, although it typically shows high renal accumulation characteristic of this chemical scaffold.